RECURSION PHARMACEUTICALS, INC. Deferred Income Tax Liabilities, Net
RECURSION PHARMACEUTICALS, INC. (RXRX) had Deferred Income Tax Liabilities, Net of $18.31 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Noncurrent › Liabilities, Other than Long-Term Debt, Noncurrent
us-gaap:DeferredIncomeTaxLiabilitiesNet · last filed 2026-08-05
- 2026-06-30: Deferred Income Tax Liabilities, Net $18.31M.
- 2026-03-31: Deferred Income Tax Liabilities, Net $18.28M.
- 2025-12-31: Deferred Income Tax Liabilities, Net $23.25M.
- 2025-09-30: Deferred Income Tax Liabilities, Net $23.31M.
| Period end | Deferred Income Tax Liabilities, Net |
|---|---|
| 2026-06-30 | $18.31M 10-Q · filed 2026-08-05 |
| 2026-03-31 | $18.28M 10-Q · filed 2026-05-06 |
| 2025-12-31 | $23.25M 10-Q · filed 2026-08-05 |
| 2025-09-30 | $23.31M 10-Q · filed 2025-11-05 |
| 2025-06-30 | $23.78M 10-Q · filed 2025-08-05 |
| 2025-03-31 | $22.44M 10-Q · filed 2025-05-05 |
| 2024-12-31 | $16.57M 10-K · filed 2026-02-25 |
| 2024-09-30 | $168.00K 10-Q · filed 2024-11-06 |
| 2024-06-30 | $0.00 10-Q · filed 2024-08-08 |
| 2024-03-31 | $528.00K 10-Q · filed 2024-05-09 |
| 2023-12-31 | $1.34M 10-K · filed 2025-02-28 |
| 2023-09-30 | $1.93M 10-Q · filed 2023-11-09 |
| 2023-06-30 | $4.34M 10-Q · filed 2023-08-08 |
| 2022-12-31 | $0.00 10-K · filed 2024-02-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |